Anand Rathi's research report highlights Sudarshan Chemical Industries' weak performance in Q2 FY26, attributed to demand slowdown in the US/Europe and customer destocking. While revenue and EBITDA saw a sequential decline, the management has trimmed the FY26 EBITDA guidance for the Heubach segment but reaffirmed long-term targets. Anand Rathi maintains a 'BUY' rating but lowers the 12-month target price to Rs1,540 due to near-term softness.